Loading clinical trials...

COMPLETEDNA

Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19

Zinc Versus Multivitamin Micronutrient Supplementation to Support Immune Health in the Setting of COVID-19 Pandemic: A Randomized Study

NCT04551339•Mayo Clinic

View on ClinicalTrials.gov

Summary

The purpose of this research study is to look at high dose zinc versus multivitamin micronutrient supplementation to support immune health in the setting of the COVID-19 pandemic.

Detailed Description

This is a two-cohort prospective randomized study intended to test the role of Zinc versus multivitamin supplementation in supporting immune health in the setting of the COVID-19 pandemic. Individuals over 50 years old or primary health care professionals over the age of 18 who have had no evidence of prior COVID-19 infection and who have been asymptomatic for 7 days prior to enrollment will be randomized at the individual level to take either PreserVision AREDS formulation soft gels or tablets with 69.6mg/day Zinc supplementation or to receive a multivitamin supplement with 11mg of zinc/day.

Eligibility

Age

18 - 90 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Age ≥50 years old OR primary healthcare professional (defined as having a job that has had direct patient contact during the COVID-19 pandemic) and ≥18 years old
•No symptoms of COVID-19 (a fever of 100.0o F or greater, OR a new cough, OR new shortness of breath, OR new sore throat, OR new diarrhea, OR new fast breathing (respiratory distress), OR new chills, OR new muscle aches (myalgias), OR new loss of smell, OR new change or loss of taste sensation) in the past 7 days
•Have a negative Elecsys Anti-SARS-CoV-2 immunoassay antibody test at screening
•Have not had close contact with a person with a LABORATORY CONFIRMED case of COVID-19 without full PPE (Close contact is defined by CDC as: Being within approximately 6 feet of a COVID-19 patient for a total of 15 minutes or more over a 24 hour period) or having direct contact with infectious secretions of a COVID-19 patient (e.g. being coughed on)) in the last 14 days
•Mayo Clinic patient who has a patient online account set up or is willing to set up an online account
•Must have a valid email address and internet service

Exclusion Criteria

•History of positive or indeterminate COVID PCR test prior to screening or Elecsys Anti-SARS-CoV-2 immunoassay antibody test positive or indeterminate at screening
•Active symptoms of COVID ((a fever of 100.0o F or greater, OR a new cough, OR new shortness of breath, OR new sore throat, OR new diarrhea, OR new fast breathing (respiratory distress), OR new chills, OR new muscle aches (myalgias), OR new loss of smell, OR new change or loss of taste sensation)) in past 7 days
•Known intolerance to multivitamins or zinc supplements from prior exposure
•Inability to complete follow-up questions or grant access to electronic health record for surveillance
•Have had close contact with a person with a LABORATORY CONFIRMED case of COVID-19 in past 14 days
•Current or former smoker less than 5 years ago
•Pregnant or breastfeeding
•Prisoner
•Any subject with known immunosuppressed state, including
•1. A history of solid organ or bone marrow transplantation
+3 more criteria

Locations (3)

Mayo Clinic in Scottsdale

Scottsdale, Arizona, United States

Mayo Clinic in Jacksonville

Jacksonville, Florida, United States

Mayo Clinic in Rochester

Rochester, Minnesota, United States

Key Dates

Start Date

September 28, 2020

Primary Completion Date

May 28, 2021

Completion Date

May 28, 2021

Last Updated

August 10, 2021

Enrollment

2,700

ACTUAL participants

Conditions

HealthyHealth Care Worker Patient TransmissionAging

Interventions

PreserVision AREDS formulation soft gels or tablets

DIETARY_SUPPLEMENT

Multivitamin with 11mg of zinc

DIETARY_SUPPLEMENT

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGPHASE1/PHASE2

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

NCT06290258

Autism Spectrum DisorderGastrointestinal Diseases+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 10, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19

Inclusion Criteria

Exclusion Criteria

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Fecal Microbiota Transplantation for Patients With Autism Spectrum Disorder.

Collection of Data and Samples From Healthy Donors for Use in Translational Research

A New Portable Device for Non-invasive Ventilatory Support

Turkish Validity and Reliability Study of PRevention of Toxic Chemicals in the Environment for Children Tool

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single- and Multiple-Ascending Doses and Food Effect of BGB-45035 in Healthy Participants and in Adults With Autoimmune Dermatological Diseases